Evidence map›Paper›PMID 28840583›Full record

Trial reportHepatology international2017

Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage.

Biplob Kumar Saha, Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Sheikh Mohammad Noor-E-Alam, Ayub Al Mamun, Sharker Mohammad Shahadat Hossain, Mohammad Ashraful Alam, Ahmed Lutful Moben, Faiz Ahmad Khondaker, Forhadul Islam Chowdhury and 4 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.International journal of molecular sciences · 2023
    Review
  12. Review
  13. [Acute-on-chronic liver failure: definition, diagnosis, and pathogenesis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Biplob Kumar SahaDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Mamun Al MahtabDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Sheikh Mohammad Fazle AkbarDepartment of Medical Sciences, Toshiba General Hospital, Higashi Oi 6-3-22, Shinagawa, Tokyo, 140-8522, Japan. sheikh.akbar@po.toshiba.co.jp.
Sheikh Mohammad Noor-E-AlamDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Ayub Al MamunDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Sharker Mohammad Shahadat HossainDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Mohammad Ashraful AlamDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Ahmed Lutful MobenDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Faiz Ahmad KhondakerDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Forhadul Islam ChowdhuryDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Ruksana RaihanDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Salimur RahmanDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Ashok Kumar ChoudhuryDepartment of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
APASL ACLF working party
Bangladesh Medical University · BDInstitute of Liver and Biliary Sciences · INToshiba (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeMobilization of bone marrow-derived stem cells by granulocyte colony stimulating factor (G-CSF) supports hepatic regeneration and may augment clinical improvement in patients with acute-on-chronic liver failure (ACLF). The aim of this study is to assess the impact of G-CSF on complications and transplant-free survival in patients with ACLF.

methodsThirty-two patients with ACLF defined by Asian Pacific Association for the Study of the Liver (APASL) criteria were openly randomized to control (group A) or intervention (group B) receiving G-CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs. The patients were followed for 90 days.

resultsSimultaneous use of G-CSF and antiviral drugs in hepatitis B virus (HBV) ACLF significantly improved survival over antiviral drugs alone. Incidence of hepatorenal syndrome and hyponatremia were reduced due to use of G-CSF. Baseline parameters of the two groups of patients were comparable. Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD), disease severity scores improved in patients treated with G-CSF, with significant difference only for the CTP score at 90 days follow-up. In addition, mean white blood cell (WBC) count at day 15 was significantly higher in G-CSF group in absence of infection compared with control group.

conclusionsG-CSF therapy improved survival and clinical recovery in HBV-ACLF. G-CSF therapy also prevented renal failure and hyponatremia. We strongly recommend use of G-CSF therapy in addition to standard medical therapy.

Indexed as

Acute-On-Chronic Liver FailureAdolescentAdultAntiviral AgentsDrug Therapy, CombinationFemaleGranulocyte Colony-Stimulating FactorHepatitis B, ChronicHepatorenal SyndromeHumansHyponatremiaLeukocyte CountMaleMiddle AgedProspective StudiesSeverity of Illness IndexAntiviral AgentsGranulocyte Colony-Stimulating FactorAcute-on-chronic liver failureGranulocyte colony stimulating factor (G-CSF)Liver damage

Identifiers

PMID28840583
OpenAlexW2748195882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.